Sun Pharma Q2 profit falls 36% as litigation costs hit earnings
60-Word AI Digest
Sun Pharma reported a 36% decline in Q2FY27 net profit to Rs 1,989 crore due to exceptional litigation and acquisition-related costs. Revenue grew 11.8%, supported by strong domestic and emerging market sales, while US formulations weakened.
Key Takeaways
- Sun Pharma reported a 36% decline in Q2FY27 net profit to Rs 1,989 crore due to exceptional litigation and acquisition-related costs.
- Revenue grew 11.8%, supported by strong domestic and emerging market sales, while US formulations weakened.
- Full details and original dispatch available below.
Sun Pharma reported a 36% decline in Q2FY27 net profit to Rs 1,989 crore due to exceptional litigation and acquisition-related costs. Revenue grew 11.8%, supported by strong domestic and emerging market sales, while US formulations weakened.
Original Publisher Attribution
This summary was curated from Economic Times.